Age Labs AS

Age Labs AS is a Norwegian life science company founded in 2017 and headquartered in Oslo. It discovers, develops and commercializes diagnostic tests for the early detection of age-related diseases. The company's approach centers on analyzing epigenetic changes in immune cells and building predictive algorithms to identify biomarkers of early disease detection and assess disease risk. Its pipeline includes a groundbreaking test for early detection of rheumatoid arthritis, a biological age predictor, and a test predicting the severity of COVID-19 infection, as well as several other promising biomarkers for diagnostics and drug response prediction. Age Labs was founded by a team of scientists, medical doctors, and engineers, giving it deep understanding of aging, genetics, and analytics. It utilizes well-characterized samples from public and private global biobanks and performs deep analysis of DNA methylation in immune cells through advanced machine learning techniques. A key differentiator is its proprietary biomarker discovery platform, EPIPHANY, which measures the regulatory domains of 99% of the human genome to create rich epigenetic profiles. Combined with pervasive access to biosamples with longitudinal clinical data, this allows Age Labs to produce extensive epigenetic reports illustrating the correlation between disease mechanisms and drug effects. Beyond diagnostics, Age Labs offers comprehensive services to the pharmaceutical and nutraceutical industries, including custom biomarker development and reports on epigenetic drug effects for use in clinical trials. It also serves the health and wellness sector with advanced biological age and disease risk measurements. The company emphasizes collaboration-based innovation, partnering with world-leading experts, global biobanks, and the largest epigenetics laboratory in the EU. It has a long-term co-development agreement with a major industry player for its Early rheumatoid arthritis test. Age Labs is a private limited company registered in Norway (reg.no 919.825.723).

Age Labs AS was founded in 2017 in Oslo, Norway, by a team of scientists, medical doctors, and engineers. The company was established with the primary aim of discovering clinically relevant biomarkers for early detection of age-related diseases. From its inception, Age Labs focused on analyzing epigenetic changes in immune cells and building predictive algorithms to identify biomarkers of early disease detection and assess disease risk. The company developed EPIPHANY, a proprietary machine learning-based biomarker discovery platform. EPIPHANY measures the regulatory domains of 99% of the human genome to create rich epigenetic profiles, enabling quantification of how genes are activated ahead of and in response to disease. Age Labs built a unique database of such profiles coupled with extensive health data from well-respected biobanks. Age Labs' first diagnostic candidate is a test for the early diagnosis of rheumatoid arthritis. The company has several R&D projects in collaboration with pharma companies and public institutions in Norway. It also developed a biological age predictor and a test predicting the severity of COVID-19 infection. The company has a long-term co-development agreement with a major industry player for its early rheumatoid arthritis test. Age Labs partners closely with world-leading experts to develop diagnostic tests based on epigenetics and DNA methylation measurement techniques, including leading global biobanks and the largest epigenetics laboratory in the EU. The company offers services to the pharmaceutical and nutraceutical industries, including custom biomarker development and comprehensive reports on epigenetic drug effects for use in clinical trials, as well as services to the health and wellness sector. As of 2025, Age Labs remains an active private limited company registered in Norway (reg.no 919.825.723), headquartered at Gaustadalléen 23A, 0373 Oslo.

• 2017

  Age Labs AS founded in Oslo, Norway.

• Developed EPIPHANY, a proprietary machine learning-based biomarker discovery platform.

• First diagnostic candidate: test for early diagnosis of rheumatoid arthritis.

• Developed biological age predictor and COVID-19 severity prediction test.

• Long-term co-development agreement with a major industry player for early rheumatoid arthritis test.

Developer of epigenetic biomarkers for early detection of age-related diseases, combining machine learning with biobank data.

• Early rheumatoid arthritis diagnostic test

  First diagnostic candidate for early detection of rheumatoid arthritis.

• Biological age predictor

  Cutting-edge biological age predictor.

• COVID-19 severity prediction test

  Test predicting the severity of COVID-19 infection.

• EPIPHANY platform

  Proprietary machine learning-based biomarker discovery platform measuring regulatory domains of 99% of the human genome.

1. 1Age Labs | Developing biomarkers for the early detection of age related diseasesagelabs.com
2. 2Aboutagelabs.com
3. 3Our Serviceagelabs.com
4. 4Age Labs AS (Norway) - Wikidatawikidata.org